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1. Introduction 
In this burgeoning era of personalized medicine we have witnessed a humongous increase 
in novel therapeutics encompassing wide range of modalities including small molecule 
drugs which can elicit their action upon encountering certain cellular component, protein 
macromolecules interfering cellular signaling pathways and nucleotide and DNA based 
therapies which alter protein/gene expression (Gonzalez-Angulo et al., 2010). The major 
factor which underscores the success of these novel therapeutic modalities is their 
propensity to reach the target site of action. Undoubtedly, the ultimate target for all these 
therapeutic modalities according to traditional paradigm is the cell. But there is a need for 
change in this paradigm since many of these modalities are targeted towards very specific 
subcellular organelles. Even though the major subcellular target even today is nucleus, there 
is growing body of evidence that other organelles also have role in many diseases (Davis et 
al., 2007). Targeting therapeutics to subcellular organelles would positively improve 
treatment in a myriad of diseases of metabolic, genetic and oncologic nature. Oncology is 
perhaps the most demanding area for organelle specific targeting since the standard therapy 
for oncology involves random interaction with cellular components and is harbinger of 
potential problems like toxicity and immunogenicity (Fulda et al., 2010; Galluzzi et al., 2008). 
Subcellular organelles in eukaryotic cells comprise of a complex organization of distinct 
membrane-bound compartments and these form the cellular basis of human physiology. 
These subcellular organelles by virtue of highly specialized metabolic functions interact 
with each other to uphold various cellular functions. Organelle biogenesis regulated by 
transcriptional networks modulating expression of genes encoding organellar proteins 
results in inheritance and proliferation of subcellular organelles such as nucleus, 
mitochondria, endoplasmic reticulum, peroxisomes and lysosomes (Hill et al., 1995; 
Nunnari et al., 1996; Warren et al., 1996). The recent developments in molecular and cellular 
biology opened up new vistas in the development of metabolic disorders due to disruption 
of organelle biogenesis. The disorders pertaining to organelles are not limited to genetic and 
metabolic origin. They are also involved in metabolic disturbances occurred during diseases 
due to infections, intoxications and drug treatments (Dhaunsi, 2005). The subcellular 
organelles are involved in wide array of diseases known to human nature like myopathy, 
obesity, type 2 diabetes, Zellweger syndrome, cancer etc., and these diseases are explained 
in detail further in the review. Thus, appropriate targeting of subcellular organelles not only 
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provides direct amelioration of genetic and metabolic disorders but also aid in cure for 
diseases whose causes underlie subcellularly.  
The approach of using nanocarriers for subcellular delivery of drugs, macromolecules and 
DNA therapeutics is proved to be more effective. This is because inherent physiochemical 
properties of the carriers such as size, shape and molecular weight are bestowed upon the 
molecule it is carrying. There is huge body of evidence reported in literature where 
nanocarriers were able to passively and actively target tumor vasculature and tumor cells 
(Magadala, 2008; Sawant, 2006; Soman, 2009; Torchilin, 2007: Yang, 2010). Now the major 
task ahead is to tailor these nanocarriers to cater the needs of subcellular targeting. This can 
be achieved by developing nanocarriers either by virtue of their inherent predilection 
toward a cellular compartment, or by attaching subcellular targeting ligands to direct 
nanocarriers to organelle of interest. For example, dequalinium (DQA)-based liposome like 
vesicles DQAsomes have inherent capability to target mitochondria for DNA and small 
molecule drugs (D'Souza et al., 2005; D'Souza et al., 2003; Weissig et al., 2001; Weissig et al., 
2000). The examples of targeting using ligand involve use of folic acid, low density 
lipoprotein, mannose-6-phosphate, transferrin, riboflavin, ICAM-1 antibody etc.,(D'Souza et 
al., 2009). This ability to control the intracellular trafficking and fate of nanocarriers is by far 
the most important advantage of using nanocarriers for organelle targeting. 
The major challenge posed for subcellular trafficking of nanocarriers is the constitution of 
the cell interior. This cell interior is very different from an aqueous buffer and it contains 
many large molecules mainly proteins, nucleic acids and complex sugars. The high 
concentration of these molecules (up to 400 grams per liter) causing the ‘macromolecular 
crowding’ is an important barrier for intracellular trafficking of nanocarriers (Ellis et al., 
2003). The complex array of microtubules, actin, and intermediate filaments organized into a 
mesh resembling lattice also influence the diffusion of solutes inside cell. The other factors 
that might perpetuate hindrance of diffusion of nanocarriers are fluid phase viscosity, 
binding to cytosolic components and collisional interactions due to macromolecular 
crowding (Garner et al., 1994). Hence, it is important to consider these factors while 
designing nanocarriers for subcellular targeting.  
Traditionally, the interactions of nanocarriers with cells and intracellular organelles were 
considered to be strongly influenced by size. But recent advances in microscopy and particle 
fabrication techniques has led us to understand the interdependent role of size, shape and 
surface chemistry on cellular internalization and intracellular trafficking (Geng et al., 2007). 
Once internalized into the cell, the most important determinant of successful delivery of 
therapeutics is the intracellular fate of endosomal content. The intracellular fate of the 
nanocarriers can be controlled depending on endocytic pathway. For example clathrin 
dependent endocytosis results in lysosomal degradation whereas clathrin independent 
internalization results in endosomal accumulation and sorting to a nondegradative path. 
The major aim of subcellular targeted delivery system is to avoid lysosomal trafficking so as 
to protect the drug or biomolecule from enzymatic degradation (Bareford et al., 2007). As 
cellular uptake and fate can be controlled by endocytic mechanism, the subcellular 
distribution can be directed by presence of additional peptide sequences that direct the 
nanocarrier to a desired subcellular site.   
Concept of targeting chemotherapeutic drugs to malignant tissue by identifying certain 
overexpressed receptors and proteins has been investigated in great detail. The concept of 
targeting to cancer can be studied by dividing the therapeutics into two classes. The first one 
being the category where drug itself is capable to act specifically on mechanisms unique to 
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malignant cells. For example, imatinib inhibits Bcr-Abl tyrosine kinase which is 
overexpressed in chronic myelogenous leukemia and trastuzumab binds and inhibits 
HER2/neu receptor which is overexpressed in breast cancers (Droogendijk et al., 2006; 
Hudis, 2007). The second category is utilization of structural moieties such as ligands and 
antibodies which will be attached to the drug to direct it toward certain features unique to 
cancer cells. For example, folate is a very good ligand to target cancer cells as folate 
receptors are over expressed in many cancers and anti-CD22 antibody epratuzumab was 
conjugated with 90Yttrium for specific diagnosis of B cell lymphoma (Allen, 2002). However, 
the selectivity to the certain tissue or cell is not sufficient to produce the desired therapeutic 
effect if the drug is not accumulated at appropriate subcellular target organelle. There also 
exists other complications such as, efflux of drug after internalization by efflux pumps such 
as p-glycoprotein (P-gp) and multidrug resistance associated protein (MRP). Thus, 
subcellular targeting of cancer therapeutics is of prime importance since drugs are designed 
to act against specific subcellular targets. For example, certain DNA therapeutics are 
expressed only after they reach nucleus and certain drugs intended for tumor regression by 
reducing endoplasmic reticulum stress response have to act at endoplasmic reticulum (Nori 
et al., 2005). 
The present review is an attempt to elucidate the importance of nanocarriers in subcellular 
targeting. The scope for subcellular targeting lies in understanding diseases affected due to 
malfunctioning of organelles. It is also very important to understand the challenges posed 
by intracellular environment for effective transport of nanocarriers. The recent targeting 
strategies employed to target each subcellular organelle is explained in detail. Thus, a 
comprehensive understanding of role of the nanocarriers in subcellular targeting and their 
application in amelioration of diseases like cancer is provided to the reader through this 
review. 
2. Cellular organelles and related disorders 
Subcellular organelles are responsible for cellular metabolic state which in turn is 
responsible for maintaining physiologic functions of tissue. Important subcellular organelles 
like mitochondria, peroxisomes, lysosomes, endoplasmic reticulum and cytoskeleton carry 
out important functions like production of energy, sorting of proteins, supporting and 
providing shape to the cell. A defect in any of the components of the network of organelles 
leads to a serious pathological state. A better understanding of diseases of organelles is of 
paramount importance in developing efficient targeting strategies. The list of cellular 
organelle related disorders is tabulated as Table-1 at the end of this section. 
Mitochondria, the powerhouse of eukaryotic cells plays a key role in energy metabolism in 
many tissues. The defects in mitochondrial functions such as respiratory coupling, reactive 
oxygen species production (ROS), enzymatic activity (fatty acid oxidation), and 
mitochondrial content and size may result in metabolic disorders such as aging, insulin 
resistance and type 2 diabetes. Most important diseases of mitochondria arise due to 
mitochondrial DNA (mtDNA) deletions which cause the formation of mutant mtDNA. 
Examples of these diseases include Kearns-Syare syndrome and Pearson syndrome which 
can be fatal in infancy or early childhood (Johannsen et al., 2009). Mitochondria also 
regulates cellular life cycle through release of cytochrome c which is an important stimulator 
of apoptosis thus indicating its role in cancer. It was also proved that mitochondrial 
oxidative and phosphorylation capacity and mitochondrial content are decreased with age 
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thus showing importance of mitochondria in aging. Mitochondrial dysfunction was also 
implicated in insulin resistance and type 2 diabetes. Recent reports suggest that `metabolic 
overload’ of muscle mitochondria is a key player in insulin resistance (Koves et al., 2008). 
Another important mitochondrial dysfunction is increased damage by ROS, which in turn 
results in cancer and neurodegenerative diseases (de Moura et al., 2010). 
Impaired ribosome biogenesis and function due to genetic abnormalities result in a class of 
diseases called ribosomopathies. These ribosomopathies result in distinct clinical 
phenotypes most often involving bone marrow failure and craniofacial or other skeletal 
defects. The ribosomopathies are generally congenital syndromes due to mutations of genes 
encoding ribosomal proteins. The first discovered ribosomopathy was Diamond-Blackfan 
anemia (DBA) which is due to mutation in RPS19 gene. DBA is a rare congenital bone 
marrow failure syndrome with a striking erythroid effect (Draptchinskaia et al., 1999). The 
other congenital syndromes linked to defective ribosome biogenesis are Schwachman-
Diamond syndrome (SDS), X-linked dyskeratosis congenital (DKC), cartilage hair 
hypoplasia (CHH), and Treacher Collins syndrome (TCS). All of these ribosomopathies 
except TCS were reported to pose risk to cancers like osteosarcoma and acute myeloid 
leukemia (Narla et al., 2010). 
Endosomes and lysosomes envisage important functions within cells including antigen 
presentation, innate immunity, autophagy, signal transduction, cell division, and 
neurotransmission. The cellular function will be compromised if undegraded substrates 
accumulate in endosomes and lysosomes due to lysosomal dysfunction. Lysosomal storage 
disorders constitute a group of genetic diseases involving dysfunction of lysosomal 
hydrolases resulting in impaired substrate degradation. Lysosomal diseases are manifested 
by enlarged lysosomes which contain partially degraded material due to 1) 
glycosaminoglycan, lipid or protein degradation defects, 2) transport across lysosomal 
membrane or 3) endosome-lysosome trafficking. The first discovered diseases of lysosomes 
are related to lipidoses and mucopolysaccharidoses. They include diseases like Tay-Sach 
disease, Gaucher disease, Fabry disease, Niemann-Pick disease, Hurler syndrome. However, 
much of the initial concept for the lysosomes and its dysfunction came from the studies of 
Pompe disease characterized by cardiomegaly, cardio respiratory failure, hepatomegaly and 
progressive muscle weakness (Parkinson-Lawrence et al., 2010).  
Peroxisomes are single membrane bound organelles which contain more than 50 different 
proteins, mainly enzymes essential for various metabolic processes, which include hydrogen 
peroxide based respiration, ǃ-oxidation of very long chain fatty acids, bile acid synthesis 
and plasmalogen biosynthesis. There exists several genetic disorders associated with 
peroxisomal system and are divided into two categories. The first category is related to 
peroxisome biogenesis and second is the single protein defects in which a single metabolic 
function is different. The examples of first category are heterogeneous group of autosomal 
recessive disorders including Zellweger syndrome, neonatal adrenoleukodystrophy, 
infantile Refsum disease and rhizomelic chondrodysplasia punctata. The examples of 
second category are X-linked adrenoleukodystrophy, hyperoxaluria type I and thiolase 
deficiency (Gartner, 2000).  
The endoplasmic reticulum (ER) apart from playing an important role in many cellular 
functions is also involved in protein folding and trafficking. The important manifestation of 
failure of the ER’s adaptive capacity is activation of unfolded protein response (UPR), which 
in turn affects various inflammatory and stress signaling pathways. UPR is closely 
integrated with inflammation, stress signaling and JNK activation. These pathways play a 
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critical role in chronic metabolic diseases such as obesity, insulin resistance, and type 2 
diabetes. It was also reported that chronic ER stress and activation of the UPR may also 
result in oxidative stress, causing a toxic accumulation of ROS within the cell (Hotamisligil, 
2010). Mice were subjected to obesity-induced stress and then treated chemical chaperones 
phenyl butyric acid and tauro-ursodeoxycholic acid. After treatment the stress was relieved 
and also there was observed an increase in insulin sensitivity and reduction in fatty liver 
disease in those obese mice, showing the link between ER induced stress and metabolic 
disorders. (Ozcan et al., 2004).  A small molecule Salubrinal was reported to protect cells 
against ER stress induced cell death in vitro and in vivo. Salubrinal prevents the 
dephosphorylation of eIF2ǂ (Boyce et al., 2005). ER stress associated disorders also include 
various neurodegenerative disorders. Recently, various neurological disorders including 
Alzheimer’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis have shown 
disruption of ER homoeostasis and up-regulation of UPR. Another recent ER related 
neurodegenerative disorder which was reported recently was `seipinopathy’, which is a 
motor neuron disease related to protein seipin. This protein seipin activates the UPR and 
induces ER stress-mediated cell death (Ito et al., 2009). Thus, targeting ER would be an 
attractive approach to ameliorate inflammatory and chronic metabolic disorders. 
The Golgi complex is an important organelle within the secretory system of the cell. Its 
organization is maintained by proteinaceous matrix, cytoskeletal components and inositol 
phospholipids. It carries out two important tasks, one being sorting of secretory cargo to 
various destinations in cell and other being modification of protein during its way to plasma 
membrane. Certain pathological conditions, pharmacological agents and over expression of 
golgi-associated proteins cause profound morphological changes of golgi apparatus. These 
morphological changes were shown by neuronal golgi apparatus in many 
neurodegenerative disorders like Alzheimer’s disease, amyotrophic lateral sclerosis, 
Creutzfeldt-Jacob disease, multiple system atrophy, Parkinson’s disease, spinocerebelar 
ataxia type 2 and Niemann-Pick type C (Fan et al., 2008). Protein glycosylation is another 
important function of Golgi apparatus. A defective glycosylation process by golgi network 
would result in disorders like congenital disorders of glycosylation and also cause acquired 
glycosylation defects associated with epidemic diseases such as cancer and diabetes (Ungar, 
2009).  
3. Role of nanocarriers in cytosolic delivery 
During past decade numerous efforts were made to efficiently direct the polymeric and/or 
nanoparticulate carriers to the organelle of choice. Most of those efforts were successful in 
delivering small molecule drugs (S. R. Yang et al., 2006), proteins (Bale et al., 2010) and 
nucleic acids (Jensen et al., 2003) to specific organelle inside cell. The major advantage of use 
of nanocarriers in cytosolic delivery arises from their characteristic properties like nanosize 
(1-100 nm), ability to carry high drug/gene payload, feasibility to modify the surface 
functionality for active targeting, ability to utilize its surface charge for passive targeting. 
The arsenal of nanocarriers investigated for organelle specific targeting includes inorganic 
and organic materials. The major units of this arsenal are liposomes (Fattal et al., 2004), 
micelles (Bontha et al., 2006), quantum dots (QDs)(Hoshino et al., 2004), polymeric 
nanoparticles (Nori et al., 2003; Yessine et al., 2004), gold nanoparticles (Bergen et al., 2006), 
magnetic nanoparticles (Xu et al., 2008), dendrimers (Samuelson et al., 2009), carbon 
nanotubes (Z. Yang et al., 2010).   
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Cellular 
Organelle 
Disease 
Defective 
gene/Function 
Clinical Features Ref 
Leigh’s syndrome 
mtDNA 
deletion 
Ataxia, seizures, 
hypotonia, lactic 
acidosis 
(Corona et al., 
2002) 
Type 2 diabetes 
GLUT4 
Translocation 
Insulin resistance 
(Johannsen et 
al., 2009) 
Mitochondria 
Progressive 
external 
ophthalmoplegia 
mtDNA 
deletion 
Developmental delay, 
lactic acidosis 
(Holt et al., 
1988) 
Obesity 
ER stress-
induced 
autophagy 
Increased body mass 
index 
(Hotamisligil, 
2010) Endoplasmic 
reticulum (ER) 
Seipinopathies Seipin/BSCL2 
Spastic paraplegia, 
muscle weakness 
(Ito et al., 2009) 
Pompe disease 
Lysosomal 
glycogen 
hydrolysis 
Cardiomegaly, 
hepatomegaly, 
Progressive muscle 
weakness 
Gaucher disease 
Lipid 
degradation in 
macrophages 
Hepatosplenomegaly, 
Osteonecrosis, 
neurodegeneration 
Lysosomes 
Fabry disease 
Glycosphingoli
pid  hydrolysis
Growth restriction, 
Cardio-respiratory 
problems, Lipid 
accumulation 
(Parkinson-
Lawrence et al., 
2010) 
Zellweger 
syndrome 
PEX gene 
Abnormal facial 
appearance 
Peroxisomes X-linked 
adrenoleukodystro
phy 
ALD gene 
Progressive 
neurodegenration 
(Gartner, 2000) 
Diamond-Blackfan 
anemia 
RPS19, RPS24, 
RPS17, RPL35A
Macrocytic anemia, 
Short stature, 
craniofacial defects 
Ribosomes 
Shwachman-
Diamond syndrome
SBDS 
Neutropenia/infections, 
Pancreatic insufficiency, 
Short stature 
(Narla et al., 
2010) 
Alzheimer’s disease
Dysregulation 
of Ca2+
signalling 
Cerebral deposition of 
amyloid plaques 
Golgi Apparatus 
Amyotrophic 
Lateral Sclerosis 
Dysregulation 
of Ca2+
signalling 
Progressive 
degeneration of cortical 
and spinal motoneurons
(Fan et al., 
2008) 
Primary biliary 
cirrhosis 
Antibodies 
against 
nucleoporins 
Cirrhosis of liver with 
destroyed bile ducts 
Nucleus 
Triple A syndrome AAAS  gene 
Hypoglycemia, 
achalasia, alacrima 
(Cronshaw et 
al., 2004) 
Table 1. Cellular organelle related disorders with specific genes involved and their clinical 
sysmptoms 
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Nanocarriers are internalized into the cell by a process called endocytosis. After the carriers 
have been successfully endocytosed, depending on the intended target, these carriers are 
directed to respective organelles of cell by means of specialized mechanisms. There exists a 
wide plethora of enodocytic mechanisms depending on the physicochemical property of the 
internalizing nanocarriers. Heterogeneity in mechanisms of endocytosis can be utilized to 
efficiently translocate the cargo to specific cellular organelles and are subjected to required 
interactions during their journey towards the target (Maxfield et al., 2004). Process of 
endocytosis can be broadly classified into two categories, one is phagocytosis that involves 
uptake of large particles, and the other is pinocytosis which involves uptake of fluid and 
solutes. Phagocytosis is observed mainly in specialized mammalian cells such as 
macrophages whereas pinocytosis is observed in all cells. Pinocytosis is underscored by four 
major mechanisms macropinocytosis, clathrin-mediated endocytosis, caveolae-mediated 
endocytosis, and clathrin- and caveolae-independent endocytosis. The endocytic route 
which is of most interest in targeting of nanocarriers is clathrin-mediated endocytosis 
because it engages mainly receptor-ligand complexes (Conner et al., 2003). Upon ligand-
receptor binding, certain adaptor proteins like adaptor protein 2 are engaged which interact 
with clathrin triskelion to trigger the formation of clathrin-coated pits. A small GTPase 
dynamin cuts the invaginated pits and release them into the cytoplasm as vesicles. Thus, the 
endocytosed cargo after being delivered into endosomes is then recycled, sorted for 
degradation or delivered to the golgi complex (Schmid, 1997). Some of the examples of 
receptors which are exploited for targeting drugs intracellularly are folate receptors, 
transferrin receptors and LDL receptors for tumor targeting, gene delivery and brain 
targeting respectively. There also exist other routes that are non-clathrin-mediated which 
involve internalization of many proteins, lipids, viruses and toxins. These are referred to as  
caveolae/raft-mediated endocytosis and cholesterol plays a crucial role in these mechanisms 
and role of dynamin is seen in some cargo (Rajendran et al., 2010). The other clathrin 
independent route of cellular internalization which involves internalization of 
glycophosphatidyl-inositol (GPI)-anchored proteins is GEEC (glycophosphatidyl-inositol 
(GPI)-anchored protein-enriched early endosomal compartment) pathway. The salient 
features of this pathway are that it is dynamin independent and bypasses the step of early 
endosome sorting by using long invaginations from the surface. Nanocarriers are thus 
directed towards their intracellular compartment using one of the above mentioned 
mechanisms and in some cases there exists interplay between the mechanisms also.  
The strategies employed for targeting nanocarriers to organelles include making the 
nanocarriers pH responsive and thus rendering them endosmolytic (e.g Poly(methacrylic 
acid), PEG-Dendrimer), use of fusogenic peptides (e.g, GALA and KALA), use of cell 
penetrating peptides (e.g Tat, Antennapedia, Tp10),  use of small molecule targeting 
sequences like triphenylphosphonium, attachment of nuclear localization sequence and 
making nanocarriers which have intrinsic endosmolytic escape capacity. However, each of 
these targeting strategies will be discussed in detail when dealing with individual organelle 
targeting. 
4. Challenges posed by intracellular environment 
The intracellular environment is very different from routine biochemical assay environment. 
Two complex fluids occupy a large portion of cellular interior, the cytoplasm and 
nucleoplasm. The cytoplasm is comprised of organelles which are dispersed, 
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macromolecules and the cytoskeletal network and chromosomal DNA constitutes 
nucleoplasm. This constitution of cytoplasm and nucleoplasm confer to their respective 
properties. Both cytoplasm and nucleoplasm thus, show a considerable degree of 
macromolecular crowding (Minton, 2006). It is very important to understand the spatial 
aspects of intracellular environment to obtain an appropriate description of cell’s behavior. 
This would help in better design of nanocarriers for organelle targeting.  
The very high total concentration of proteins, nucleic acids and complex sugars inside cell 
give rise to ‘macromolecular crowding’, which has energetic consequences which affect 
cellular functions like diffusion of proteins within cytosol. The important effects of 
macromolecular crowding can be formation of protein aggregates such as amyloid deposits 
and reduction in the diffusion rate of the diffusing particle. A new technique called 
cryoelectron tomography provided a direct evidence of crowded state of cell interior. The 
pictures showed a high density of actin filaments and ribosomes confirming that cytoplasm 
consists of huge compacts of macromolecules rather than freely diffusing and colloiding 
macromolecules (Medalia et al., 2002). Nanocarriers depict macromolecules because of their 
size, shape and surface functionality thus it is quite imperative that nanocarriers should be 
able to overcome this entire gamut of macromolecular crowding inside cell for efficient 
targeting. 
The complex environment of intracellular milieu is mainly attributed by factors like 
immobile barriers, molecular crowding and binding interactions. These factors hinder the 
intracellular diffusion. The effect of immobile barriers and crowding agents on translational 
mobility was assessed using multi-photon fluorescence correlation spectroscopy. The 
immobile barriers were mimicked by using silica-based nanostructures and macromolecular 
crowding agents were mimicked by high molecular mass dextrans. The data suggested that 
when tagged molecules like dextran-tetramethylrhodamine or eGFP-CaM are placed in 
heterogeneous environments as described above, there exist various mechanisms of 
diffusion. The first one being characterized as Fickian diffusion which is normal but slowed 
diffusion due to crowding. In some data it was also observed that molecules have a less 
hindered mobility due to relative size between tracer molecule and dimensions of crowding 
agents. In other data the molecule showed a subdiffusive like behavior and hindered 
mobility and it is explained by the idea that molecules can be trapped in either mobile or 
immobile cages (Sanabria et al., 2007).   
There exists a pH gradient across many biological membranes. The pH gradient play 
important role in cellular functioning like modulating bilayer asymmetry, loading of 
vesicles with molecules bearing charge like amino acid, peptide, protein, controlling of 
fusion process and maintaining degradative functions in acidic organelles. It was observed 
that vesicles with a pH gradient across their membrane have different electrophoretic 
mobilities and is due to pH associated changes in surface density (Hope et al., 1989). Using 
capillary electrophoresis with laser induced fluorescence detection it was shown that pH 
gradient across liposomal membrane induce electrophoretic mobility shifts based on 
capacity theory. Moreover, it was also proved that mobilities of acidic organelles are in 
congruency with predictions based on liposomal models (Chen et al., 2007). 
The major determinants of cytoplasmic rheology are fluid-phase viscosity and translational 
diffusion coefficient. For smaller solutes the collisions with intracellular components was 
determined to be the principal diffusive barrier which hindered translational diffusion (Kao 
et al., 1993). Seksek et al have reported that macromolecule size solutes (FITC-dextrans and 
Ficoll) when microinjected into fibroblasts and epithelial cells, the translational diffusion 
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slowed three- to four folds in cytoplasm and nucleus compared with water and the degree 
of slowing did not depend on molecular size up to at least 300 A° gyration radius (Seksek et 
al., 1997). The mobility of DNA in cytoplasm after it is released from a nanocarrier is a very 
important aspect to assess the efficacy of gene delivery using nanocarriers. Mobility of DNA 
in cytoplasm is also assessed by the same parameter described above which is translational 
diffusion. Fluorescein-labeled double stranded DNA fragments of increasing sizes (in base 
pairs (bp): 21, 100, 250, 500, 1000, 2000, 3000, 6000) were microinjected into cytoplasm and 
nucleus of HeLa cell and their diffusion was measured using photobleaching. Results 
indicated that the translational diffusion of smaller DNA fragments was not greatly 
impeded but the larger DNA fragments showed little or no diffusion especially for DNAs > 
2000 bp. Such a slowing of DNA mobility is largely due to a combination of collisional 
interactions and macromolecular crowding effects. Interestingly, in nucleus DNA fragments 
of all sizes showed no mobility and this immobilization was attributed to extensive DNA 
binding to nuclear components like histones (Lukacs et al., 2000).  
In an attempt to establish the exact mechanism involved in this reduced mobility with 
increase in DNA size, the diffusion studies were performed in presence of crowded 
solutions containing predominantly actin filaments. The results indicated that actin mesh 
rather than cytoplasmic crowding is the major barrier for cellular diffusion of large DNA. 
This result was consolidated by fact that when actin filaments were disrupted using 
cytochalasin D (5 µM) the size dependent reduction in mobility was not seen (Dauty et al., 
2004). Thus, cytoskeletal barrier is an important limiting factor for non-viral gene delivery 
vectors. However, some viruses such as SV40 antigen overcome this barrier by activating 
tyrosine kinase-induced signaling cascades which dissociates the filamentous actin.   
5. Effect of size and shape of nanoparticles in subcellular trafficking 
Particle size of the nanocarriers have played a pivotal role in undermining many useful 
characteristics of the nanocarriers like enhanced permeation and retention (EPR) effect, 
cellular internalization and cellular trafficking. For example, to efficiently utilize the EPR 
effect the nanocarrier must fall in between a size range of 10 nm to 100 nm. If the nanocarrier 
is smaller than 10nm they will be rapidly cleared by kidneys and larger carriers are cleared 
by reticuloendothelial system. Particle sizes of nanocarrier also influence some of the very 
important characteristics such as degradation and clearance. It was reported that 
degradation of particles is size-dependent and degradation products formed within the 
particle can diffuse freely to the surface if they are from smaller particles (Dunne et al., 2000; 
Panyam et al., 2003). Particle size more importantly dictates the endocytic mechanism which 
will be engaged to internalize the nanocarrier. Large particles 2-3 µm are internalized by 
phagocytosis by macrophages. Internalization of considerably smaller particles >1 µm is 
facilitated by macropinocytosis, much smaller nanosacle range particles are internalized by 
caveolar-mediated (~60 nm), clathrin-mediated (~120 nm) and clathrin-independent and 
caveolin-independent endocytosis (~90 nm) processes (Petros et al., 2010). However, it is not 
just the particle size that governs the properties of the nanocarriers, particle shape also have 
a strong impact on the carrier performance. 
The impact of particle shape was poorly understood earlier, perhaps due to lack of 
appropriate fabrication techniques. Recently, many fabrication techniques for synthesis of 
conventional non-spherical particles were reported in literature. The fabrication methods 
generally use techniques such as lithography, microfluidics, film-stretching, non-wetting 
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molding and photopolymerization. Many times, these techniques will be used in 
combination. By virtue of these fabrication methods particles of various morphologies like 
disks, toroids, ellipsoids form a variety of polymers such as poly(ethyleneglycol), poly 
styrene, poly vinyl alcohol, poly lactide-co-glycolide, poly(methylmethacrylate) etc, were 
synthesized and their properties were evaluated. Non-wetting molding and film-stretching 
methods produced a variety of two and three dimensional shapes in diameters of nanoscale 
(Champion et al., 2007).  
Polystyrene particles of various shapes and sizes were prepared and their phagocytosis was 
studied in alveolar macrophages(Champion et al., 2006). The polystyrene particles were 
fabricated into six different shapes encompassing various shape characteristics such as 
aspect ratio, size, concavity and curvature. The geometric shapes of particles fabricated are 
spheres (radius 1.0-12.5 µm), oblate ellipsoids (major axis 4µm, aspect ratio 4), prolate 
ellipsoids (major axis 2-6 µm, aspect ratio 1.3-3), elliptical disks (EDs) (major axis 3-14 µm, 
aspect ratio 2-4, thickness 400-1,000 nm), rectangular disks (major axis 4-8 µm, aspect ratio 
1.5-4.5), and UFO shaped particles (sphere radius 1.5µm, ring radius 4µm). These poly 
styrene particles were investigated in their nonopsonized and IgG-opsonized forms. It was 
reported that particle shape at the contact, not the size, dictates whether cells will proceed 
with phagocytosis or merely spread on the particle size. However, particle size was shown 
to affect the completion of phagocytosis especially when volume of particle is greater than 
macrophage volume. The interesting observation of this study was that except for spheres 
point of initial contact of particle with cell was major determinant in internalization. It was 
reported that internalization did not occur when cells initial point of contact was concave 
region whilst, attachment to dome or ring regions proceeded internalization process. The 
mechanism of internalization as elucidated by formation of actin cup was also influenced by 
point of initial contact and was in accordance with observations reported above (Champion 
et al., 2006). The following Figure 1 depicts the influence of point of initial contact on 
internalization of particles. 
The influence of particle shape on in vivo circulation and its extravasation through 
microvasculature was also investigated in rodents using filamentous micelles (Geng et al., 
2007). Cylindrically shaped filamentous micelles called filomicelles were fabricated using 
hydrophilic polyethyleneglycol (PEG) and hydrophobic polycaprolactone (biodegradable) 
or polyethylene (nonbiodgeradable). These stable filomicelles were fluorescently labeled 
and then compared with spherical micelles for transport and trafficking after intravenous 
injection into mice. Filomicelles have shown to exist in circulation for upto one week and 
filomicelles with longer initial lengths showed increased circulation times. It was also shown 
that these filomicelles enter cells under static conditions but under conditions of constant 
flow due to hydrodynamic shear cylindrical filomicelles are pulled off from phagocytes as 
they come into contact. It was also reported that when a chemotherapeutic agent Paclitaxel 
was loaded into these filomicelles, they shrunk tumors with longer filomicelles being more 
effective at a given dose (Geng et al., 2007). 
A novel top-down lithographic fabrication method called PRINT (Particle Replication In 
Non-wetting Templates) was used to prepare micro and nanoparticles from cationic, cross 
linked poly (ethyleneglycol) hydrogels. These particles were then investigated for the 
interdependent effect of size, shape and surface charge (zeta potential) on cellular 
internalization by human cervical carcinoma epithelial (HeLa) cells. Using this technology 
three different types of particles were fabricated, a micrometer-sized series of cubic-shape 
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Fig. 1. Scanning electron micrographs  (A-C) and actin staining (D-F) depicting the influence 
of initial point of contact on phagocytosis. In figures A-C cells and particles were colored 
brown and purple, respectively. (A) The elliptical disk (ED) which was opsonized can be 
seen to be engulfed by the cell. (Scale bar: 10µm). (B) The flat side of the particle (ED) 
attached by the cell.  (C) A spherical particle with approximately half of its surface was 
covered by the cell membrane. Figures D-F depict the overlays of bright and fluorescent 
images after fixing and staining actin cells with rhodamine phalloidin. (D) At the leading 
edge of membrane new actin polymerization enables membrane to progress over an 
opsonized ED and formation of actin ring can be seen. (E) No actin cup or ring is visible 
when cell is attached to the flat side of the opsonized ED. (F) Formation of actin cup at the 
end of the sphere as internalization begins after attachment. (Scale bars in D-F: 10µm.) 
Numbers of cells observed for each orientation of each particle were not less than five. 
Figure was obtained with permission from reference by (Champion et al., 2006) © The 
National Academy of Sciences of the USA. 
particles, micrometer-sized cylindrical particles with same heights but different diameters 
and finally a cylindrical-shape nanoparticle series. A very important observation of this 
work was that particles upto 3 µm sizes were internalized by the nonphagocytic HeLa cells. 
This contradicts the current dogma that upper limit of the size of any nanoparticle to be 
internalized into cells by means of nonspecific endocytosis is 150 nm.  It was reported that of 
all shapes, rod like cylindrical nanoparticles with high aspect ratio (ratio of height to 
diameter) were internalized ~4 times faster than low-aspect ratio particles, and cylindrical 
particles with varying size and volume have shown varying degrees of internalization. It 
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was also shown that 84% of positively charged nanoparticles were internalized in 
comparison with <5% of identically shaped negatively charged indicating the importance of 
surface chemistry in cellular internalization (Gratton et al., 2008).  
Similarly, Huang et al fabricated mesoporous silica nanoparticles with various shapes and 
aspect ratios and their cellular internalization was studied. The three shapes fabricated were 
spheres, short and long rods each with similar diameter but with different aspect ratios 
(ARs, 1, 2, and 4). The results indicated that particles with larger aspect ratios were 
internalized at faster rates and to a greater extent. It was also reported that long rod-shaped 
particles disrupted the cell cytoskeleton, where as spherical and short rod shaped particles 
did not.  Finally, the long rod-shaped nanoparticles reduced the cell viability to a greater 
extent when compared to short-rods and spheres (Huang et al., 2010). 
6. Intracellular fate of nanocarriers and factors affecting the intracellular fate 
Nanocarriers are used profusely for many biomedical applications like drug delivery, gene 
delivery, imaging, targeted chemotherapy etc. Thus, it is of great importance to understand 
the intricate complex processes that regulate the intracellular fate of nanocarriers as they 
govern major properties of nanocarriers like biocompatibility, targeting efficiency etc.,. The 
traditional paradigm of intracellular fate of nanocarriers suggest that after cellular 
internalization, nanoparticles gets entrapped in endosomes which later fuse with acidic 
lysosomes and results in degradation of its contents (Watson et al., 2005). However, in 
recent years nanocarriers are designed in a way to protect its contents from lysosomal 
degradation. The strategies involve use of targeting ligands to directly target the organelle 
of interest, make nanocarriers pH sensitive thus making them endosmolytic or using 
alternative endocytic mechanisms which evade lysosomal degradation. Thus, intracellular 
fate of nanocarriers has become highly subjective and varies depending on physical and 
chemical characteristics of the nanocarrier. 
The poly(lactide)-co-glycolide (PLGA) nanoparticles (NPs) were shown to follow a typical 
endocytosis-exocytosis route. The NPs initially encounter endosomes followed by retrieval 
or escape from the compartment and then interact with exocytic organelles of the cell like 
endoplasmic reticulum, golgi apparatus and secretory vesicles. PLGA NPs avoid lysosomes 
and are capable to bypass intracellular digestive compartment (Cartiera et al., 2009), 
Whereas, polystyrene NPs once internalized were not contained in endosomes or lysosomes 
but were found to localize within mitochondria of cell lines. It was also reported that 
polystyrene NPs were accumulated within bile canaliculi suggesting that NPs can be 
eliminated within bile. In another study where intracellular fate of a Tat-conjugated 
quantum dots were investigated, the results have shown that Tat peptide was digested in 
lysosomes by enzymes leaving the Tat-detached quantum dots in lysosomes for excretion 
(Xiong et al., 2010).   
Liposomes are another important class of nanocarriers whose intracellular fate has been 
investigated. Tat-peptide conjugated liposomes were fluorescently labeled using Rhodamine-
phosphatidylethanolamine (Rh-PE) and their intracellular fate was investigated using epi-
fluorescence and differential interference contrast microscopy. The results have shown a 
typical time dependent pattern of distribution of liposomes inside the cell. The localization of 
intact  liposomes within cytoplasm was observed after 1 hr. The liposomes after 2 and 4 hr 
were seen clustered in perinuclear region and at 9 hr the degradation of liposomes was 
observed. Finally, after 24 hr no liposome was seen inside cell (Torchilin, 2005).    
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7. Current approaches and strategies for optimal organelle targeting 
7.A NUCLEUS 
Nucleus is perhaps the most important cellular organelle which needs efficient targeting 
because it is the ultimate target for treatment for genetic diseases. Gene therapy which 
underscores the use of therapeutic DNA usually fails due to lack of transfection of DNA into 
nucleus. Thus it is very important to develop strategies that improve targeting of DNA 
molecules directly to nucleus. The prime barrier for a DNA or any molecule whose intended 
site of action is nucleus is the nuclear envelope. Both active and passive transport in and out 
of nucleus takes place via nuclear pore complexes (NPCs) embedded in nuclear envelope.  
The NPC structurally can be divided into three components, a central domain and a nuclear 
and cytoplasmic ring constructed from 50 different nucleoporin proteins. The central 
domain forms a aqueous channel through the nuclear envelope of ~9 nm in diameter. 
Passive diffusion is the mechanism underlying translocation of small molecules. Whereas, 
molecules >45 kDa must possess a nuclear localizing signal (NLS) which are recognized by 
importin family proteins which in turn mediate the nuclear transport (Poon et al., 2005).  
In order to efficiently deliver the cargo into the nucleus we have to overcome two major 
impediments. One is the passage through cytoplasm and other is translocation via nuclear 
membrane. The common consideration in both these constraints is the size of the cargo. As 
described in previous sections, cytoplasm is a highly crowded environment containing 
organelles, macromolecules and cytoskeleton forming a `cytoplasmic sieve’. Large 
molecules thus diffuse slowly in cytoplasm, in comparison with their diffusion in water. To 
overcome this impediment a successful strategy was provided by taking example of 
trafficking of herpes simplex virus (HSV). HSV utilizes the microtubule cytoskeleton motor 
proteins dynein and kinesins for nuclear transport (Dohner et al., 2005). The transport of 125 
nm HSV caspid to nucleus clearly demonstrates that by utilizing the cytoskeleton we can 
efficiently diffuse large molecules through cytoplasm to nucleus. In order to counteract the 
second barrier which is presented by NPC, the cargo should be packaged to a size/structure 
below ~40 -60 nm and a NLS has to be attached (Pante et al., 2002). Thus, it is imperative to 
consider these two barriers in designing strategies to deliver macromolecules like DNA to 
nucleus.  
The most important strategy to target nucleus is by using DNA binding proteins. Most DNA 
binding proteins are inherently equipped with NLS to enable them to efficiently translocate 
into the nucleus to perform necessary functions. GAL4, a yeast transcription factor whose N-
terminal 147 residues contain a DNA binding domain and the first 74 amino acids of this 
domain function as NLS. Thus, it was reported that enhanced GAL4-mediated gene delivery 
was achieved when a large SV40 T antigen was linked to the complex. This addition resulted 
in switching of nuclear import from an importin ǃ-mediated to an importin ǂ/ǃ-mediated 
pathway(Chan et al., 2001). Nuclear factor κ B (NF κB) also has a NLS through which it 
internalizes into nucleus via a importin dependent fashion. The NFκB protein p50 which 
have NLS was shown not only to enhance the nuclear transport of DNA but also enhanced 
the migration of DNA towards nucleus from cytoplasm through microtubules (Mesika et al., 
2005).  
There has been an increase in considerable amount of interest in recent years in active 
targeting to nucleus. This stemmed from the rise of non-viral gene therapy to deliver large 
molecules of DNA to the nucleus. Initially, active targeting involved co-administration of 
NLS peptide after microinjection of DNA, but with this strategy, there remains a question 
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whether NLS and DNA remain bound in endosome or cytoplasm, or even after binding of 
NLS to importin. Thus coupling of NLS peptides to DNA emerged as a more attractive 
approach for nuclear targeting.  But this strategy was not highly efficient as increase in gene 
expression was limited to 2 to 5 fold only (Pouton et al., 2007). An alternative to this strategy 
would be attaching a polypeptide or protein containing an NLS to the DNA by using 
covalent coupling, reversible interaction or streptavidin-biotin binding technology. This 
strategy of attaching a NLS as a part of protein or polypeptide would make NLS more likely 
to be presented with appropriate tertiary structure to impinge strong binding to the 
importin or relevant nuclear transport protein involved (Pouton et al., 2007). NLS-
streptavidin was coupled to DNA molecules with a single biotinylated nucleotide end and 
microinjected into cells or administered to digitonin-permeabilised cells to investigate 
uptake of DNA by nucleus. This study reported that NLS-mediated transport delivered the 
DNA into nucleus, but there exists a size limitation of approximately 1 kb DNA.  
Another strategy which is still in its infancy is the use of multifunctional fusion proteins 
which are equipped with a DNA binding domain and nuclear import moiety which allows 
efficient delivery and trafficking of DNA to the nucleus. A recombinant fusion protein was 
constructed based on  multidomain structure of the bacterial pseudomonas exotoxin A. The 
protein consists of ErbB-2 specific antibody which imparts target cell specificity, the 
exotoxin A translocation domain executes endosomal escape and a DNA binding domain 
from yeast GAL4 enable sequence-specific high affinity binding to DNA. Transient 
expression of the luciferase gene was observed and correlates with the amount of carrier 
protein in the complex and when carrier protein was truncated lacking either cell 
recognition domain or translocation domain resulted in failure of DNA transfer (Fominaya 
et al., 1996).  
7.B Mitochondria 
Mitochondria are distinct cellular organelles which occupy a major volume of animal cell 
cytoplasm. Mitochondria are also called as power plants of the cell because they provide the 
bulk of cellular ATP. Mitochondria structurally are composed of two membranes and are 
primarily composed of phospholipid bilayers with proteins embedded in them. Because of 
presence of two membranes there exists two aqueous spaces, the inner one being called the 
matrix space and the one between the membranes is called the intermembrane space. The 
outer membrane consists of channel-forming protein called voltage-dependent anion 
channel (VDAC) and limits the passage of molecules to intermembrane space to a MW of 
5000 Da or less. Proteins and other large molecules use a unique protein import apparatus to 
cross the outer membrane. The inner membrane has a composition distinct from outer 
membrane, it is more proteinaceous and contains an unusual phospholipid, cardiolipin. The 
major function of mitochondria, the ATP synthesis occurs in matrix thus inner membrane is 
then major barrier which governs the transport of molecules in and out of matrix. Inner 
membrane is thus embedded with many transporters which allow specific compounds with 
a specific ligand to reach matrix space. One of those transporters is the ATP/ADP carrier 
which transfers ATP out from matrix space while simultaneously allowing ADP to cross 
inner membrane (Mukhopadhyay et al., 2007). 
Mitochondrial proteins synthesized in cytosolic ribosomes are translocated into 
mitochondria by receptor-translocator complexes present in inner and outer membranes, 
which are TIM (translocator inner membrane) and TOM (translocator outer membrane) 
respectively. An N-terminal leader sequence of protein is recognized by the TIM and TOM 
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complexes and thus enables protein to be translocated into mitochondria. Apart from their 
central role in energy metabolism and bioenergetics, mitochondria are also involved in 
regulation of apoptotic cell death, calcium metabolism, cardio protection and free radical 
formation (Biasutto et al., 2010). Thus, targeting mitochondria would benefit in alleviating 
many pathological conditions whose causes underlie in mitochondrial functioning. 
The initial attempts to target mitochondria involved use of hydrophobic molecules which 
take the advantage of the hydrophobic nature of the membrane and diffuse across the 
membrane. The first compound showing that property was triphenyl phosphonium ion 
(Jauslin et al., 2003). We can either attach functional groups to the phosphorous atom or the 
phenyl rings can be modified to attach drugs and thus carried into the matrix space and 
released there. The important advantage of triphenyl phosphonium (TPP) or a methyl 
derivative of TPP is that without requiring a receptor they can penetrate into mitochondria 
due to their hydrophobicity and delocalized positive charge (Jauslin et al., 2003). TPP has 
been proved useful in targeting antioxidants to mitochondria which protect oxidative 
damage (Adlam et al., 2005; Sheu et al., 2006). Polymer based targeting of mitochondria was 
also investigated by attaching TPP covalently to HPMA copolymer. Results have indicated 
that TPP was able to transport electrically neutral and very low molecular weight conjugates 
(Callahan et al., 2006). A more recent study involved targeting of cyclosporin A to 
mitochondria using TPP. The results have shown that this conjugate amplified CsA activity, 
which is to abolish cell necrosis which in turn is due to deprivation of oxygen and glucose 
(Malouitre et al., 2009). TPP was also used to target peptide nucleic acid to mitochondria for 
treatment of mtDNA diseases (Muratovska et al., 2001). Dequalinium (DQA) is another 
dicationic amphiphilic compound which has the potential to localize exclusively in 
mitochondria. Another advantage of DQA is that it has shown to form liposome like 
aggregates in water called DQAsomes which can also bind plasmid DNA. Weissig et al have 
demonstrated that DQAsomes complexed with plasmid DNA can transport and release 
nucleic acid into mitochondria after interacting with mitochondrial membrane (D'Souza et 
al., 2003).     
Mitochondrial proteins encoded in nucleus carry targeting signal that allow delivery into 
mitochondria through translocases, TIM and TOM. Peptides representing those signal 
sequences termed as mitochiondrial-targeted peptides are used to target mitochondria. 
Yamamoto and co-workers attached mitochondrial targeting peptide to n-trioctlyphosphine 
oxide (TOPO)-capped quantum dots and this conjugate exhibited a strong mitochondrial 
localization in contrast to quantum dots covered with a control peptide (Hoshino et al., 
2004). In another attempt to internalize peptide nucleic acid into isolated mitochondria, a 
presequence of cytochrome c oxidase subunit VIII was used (Chinnery et al., 1999). These 
peptides thus provide a promising approach for targeting small molecules and nucleic acids 
to mitochondria.  
Mitochondrial targeting also witnessed some reports where without any targeting sequence 
or lipophilic cation, molecules were localized in mitochondria. Block copolymer micelles 
that were made of poly(caprolactone)-b-poly(ethylene oxide) were unexpectedly localized 
into mitochondria suggesting these micelles have a important role in mitochondrial 
targeting (Savic et al., 2003).  
There are many strategies used to target mitochondria in the pretext of cancer. Cardiolipin a 
mitochiondrial inner membrane phospholipid is important component for efficient 
functioning of various carriers, protein import apparatus and for respiratory chain. 
Cardiolipin also plays an important role in apoptosis as it is an essential collaborator for 
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caspase-8, t-Bid and Bax thus indicating an avenue for mitochondrial targeting which can 
promote or prevent apoptosis. Mitochondrial channels like VDAC (porin), Shaker-type K+ 
have been shown to play a role in apoptosis. Thus, these channels can be attacked to 
promote apoptosis in cancer cells. Certain mitochondriotropic polyphenols having 
antioxidant activity were used to counteract the production of reactive oxygen species. 
Antioxidants quercetin and resveratrol were shown to preferentially accumulate in 
mitochondria when conjugated with TPP (Biasutto et al., 2010).  
7.C Endoplasmic Reticulum 
Endoplasmic reticulum (ER) is an important intracellular organelle involved in expression 
and control of functional proteins required for the cellular communication and activity. ER 
is characterized by extensive membrane surfaces in cell extending from the nuclear envelope 
to cell periphery. ER embedded with ribosomes is known as rough ER and it’s continuity 
with smooth membranes that provide surfaces for vesicle formation at ER exit sites. ER is 
involved in many key activities of the cell including biosynthesis of lipids, assembly and 
folding of proteins, homeostasis and control of Ca2+ signaling. Protein assembly and folding 
by the ER is the most important function which affects many essential biological activities. 
Improper handling of protein in ER leads to development of a myriad of unrelated diseases 
affecting different organs like heart, thyroid, kidney etc. (Aridor et al., 1999). The protein 
assembly and folding are controlled by two execution pathways. In one pathway, proteins 
are directed towards proteasome degradation from a folding pathway and in other folded 
and assembled proteins are transported to golgi complex by virtue of activity of cytosolic 
protein complex, the COPII coat.    
Dysfunctional processing of proteins by ER can lead to either loss or gain of essential 
cellular functions. Loss of function of protein is the basis of many ER derived diseases and 
arise due to mutations that hinder protein folding which eventually lead to retention and 
degradation in ER.  One such example is the loss of cystic fibrosis transmembrane 
conductance regulator (CFTR) function due to mutation of protein leading to lung fibrosis 
(Rowe et al., 2005). Inhibition of degradation of mutant protein leading to accumulation and 
aggregation of protein is the underlying cause of gain of function related ER processing 
diseases. This leads to generation of signals by transmembrane receptors in ER and can lead 
to induction of inflammatory response and can culminate in cellular apoptotic response 
leading to degenerative disease. A mutated protein ǂ 1-antitrypsin which regulates elastase 
activity when not efficiently degraded gets accumulated in ER and lead to propagation of 
inflammatory response. This inflammatory response results in liver injury along with 
normal manifestation of lung emphysema (Hidvegi et al., 2005).  
Unfolded protein response (UPR) is an extensive adaptive response that initially 
upregulates cellular biosynthetic activities in response to signals generated from the ER. 
Chronic UPR activation leads to apoptotic cell death and UPR is observed in many 
neurodegenerative diseases. 
Stabilization of protein folding is the prime target to alleviate a variety of ER derived 
diseases. When protein kinetics of ΔF508 mutant of CFTR were modulated at reduced 
temperatures (27°C) the protein efficiently folds and egresses from the ER (French et al., 
1996). Chemical chaperones can also be used to support protein folding without direct 
binding to mutant proteins. One important class of chemical chaperones is presented by 
osmolytes. These osmolytes like glycerol, trimethylamine-N-oxide or deuterated water 
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increase the hydration layer of folding intermediates in the ER. The other classes of chemical 
chaperones include dimethyl sulfoxide, 4-phenyl butyrate (4-PBA). 4-PBA an FDA approved 
drug for urea cycle disorders was also found to be effective in reducing UPR in cells and 
animal models. Thus, these chemical chaperones can be utilized to target certain proteins to 
ER. Another approach for targeting protein in ER is using hydrophobic ligands capable to 
enter cells and stabilize protein function. Glibenclamide a sulfonylurea, binds to the 
sulfonylurea receptor protein SUR1 and rescues the ER-retained mutated SUR1 to support 
delivery and expression of Kir6.2 which otherwise lead to development of congenital 
hyperinsulinism (Yan et al., 2006). 
The above strategies can be applied to efficiently target endoplasmic reticulum to alleviate 
ER derived disease due to improper processing of proteins.  
7.D Endosomes / lysosomes 
Endocytosis is the primary route of uptake of many small drugs and macromolecular 
therapeutics. Especially, the receptor mediated endocytosis is probably the most efficient 
one for specific uptake of therapeutics. The receptor mediated endocytosis usually begins 
with uptake of molecule at plasma membrane by binding to cell surface receptors at clathrin 
coated pits. This complex then in the form of clathrin coated vesicles called endosomes, 
enters the cell. These early endosomes then mature into late endosomes and then fuse with 
and release their contents into lysosomes, where the contents are degraded. So targeting of 
endosomes and lysosomes has to be studied together since the entry of molecules into these 
organelles in interconnected. Moreover, even though targeting of therapeutics to endosomal 
uptake pathway enhances the intracellular concentration of molecules up to 1000 fold it is 
not devoid of demerits (Breunig et al., 2008). Since the end point of the therapeutics like 
peptides, proteins, DNAzymes is either nucleus or any other organelles, these molecules 
have to be released in cytosol intact. But unfortunately acidic pH and degradative enzymes 
in lysosomes degrade those molecules and render them ineffective. Thus, targeting 
endosomes/lysosomes have to be studied in two contrasting parts. In one part we discuss 
strategies to enhance intracellular uptake of therapeutics mediated by receptor mediated 
endocytosis which explains direct targeting to endo-/lysosomes. The other part involves 
strategies applied for escape of molecules from endo-/lysosomes so that therapeutics are 
not degraded and delivered intact into cytosol for further action into other organelles. 
7.D.1 Targeting endosomes / lysosomes 
Apart from being the channel for degradation and recycling of molecules and receptors at 
cell surface, endosomal system is also an essential site of signal transduction. So, targeting 
endosomes or endosomal signaling pathway has very important therapeutic effects. For 
example, endosomal ECE-1 (endothelin-converting enzyme 1) is important target for 
diseases involving inflammation and pain, an ECE-1 inhibitor exhibited an anti-
inflammatory effect thus proving the potential of targeting endosomal signaling pathway 
(Cattaruzza et al., 2009). The other important way of targeting endosomes involves use of 
cell surface receptors like folate, transferrin, and low density lipoprotein (LDL) receptors. 
Several anti cancer drugs like doxorubicin, cisplatin, chlorambucil, mitomycin, gemcitabine 
and DNAzymes were efficiently targeted to tumor cells through transferrin receptors 
(Breunig et al., 2008). 
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Lysosomes apart from serving as acidic organelles involved in degradation of extracellular 
molecules, are also responsible for turnover of intracellular cytosolic molecules and 
organelles by a process known as autophagy. In this process lysosomal enzymes are 
secreted by rough endoplasmic reticulum and reach lysosomes via mannose-6-phosphate 
receptors. The deficiency of lysosomal enzymes can lead to accumulation of missing 
enzyme’s substrate and eventually leads to metabolic disorders called lysosomal storage 
diseases like pompe’s disease, gaucher’s disease, fabry’s disease and hurler-Scheie 
syndrome (Pastores et al., 2005). Thus, targeting of degradative enzymes to lysosomes 
would result in reversing of those disease conditions. For example, enzyme replacement 
therapy with agalsidase alpha which is an exogenous source of ǂ-galactosidase A is proved 
to be effective in treatment of Fabry’s disease (Mehta et al., 2010). 
7.D.2 Endo-/lysosomal escape strategies  
The important strategy for endo-/lysosomal escape of protein and nucleotide therapeutics is 
to use pH responsive carriers.  These pH responsive carriers utilize the low pH of 
endosomes to release the therapeutics into the cytoplasm. Several approaches have been 
proposed to achieve this task like use of fusogenic peptides, use of pH sensitive polymers 
use of cell penetrating peptides or photochemical internalization which involve rupture of 
endosomal membrane loaded with photosensitizing molecules. 
The fusogenic peptides at pH 7 assume a random coil structure and when encounters acidic 
pH, a conformational transition takes place which enables their interaction with 
phospholipid membrane resulting in pore formation or lysis or membrane fusion. These 
peptides can be of natural origin like N-terminus of hemagglutinin subunit HA-2 of 
influenza virus or synthetic like WEAALAEALAEALAEHLAEALAEALEALAA(GALA), 
orWEAKLAKALAKALAKHLAKALAKALKACEA (KALA). Intracellular delivery of many 
therapeutics including oligonucleotides, peptides or plasmid DNA was enhanced when 
these peptides were incorporated into delivery systems. When a siRNA to silence 
suppressor of cytokine signaling 1 (SOCS1) gene was loaded in an octaarginine (R8) 
modified lipid envelope type nanoparticles (R8-MEND) with a fusogenic peptide GALA, 
successful endosomal escape was achieved. The results have shown that siRNA loaded 
R8/GALA- MEND nanoparticles efficiently suppress endogenous gene expression (Akita et 
al., 2010).  
Many cationic polymers have an intrinsic endosmolytic activity which results in swelling 
and rupture of endosomes due to proton sponge effect. Cationic polymers such as 
polyethyleneimine (PEI) can result in endosomal escape and subsequent release of DNA 
into cytoplasm by two mechanisms. One involves proton sponge effect where PEI buffers 
endosomal environment resulting in osmotic swelling of vesicle and subsequent burst of 
endosome which leads to release of DNA into cytoplasm (Behr, 1994). Other involves direct 
interaction of PEI with endosomal membrane creating holes in the membrane (Bieber et al., 
2002). In another attempt, hydrophobic groups were attached to dendrimers by an acid-
sensitive acetal linkage and thus in acidic conditions the complex will lose its hydrophobic 
molecules making it hydrophilic and thus destabilizing the micelle and allow escape of drug 
doxorubicin (Gillies et al., 2005). 
Inspite of the advantages offered by above strategies for delivery of therapeutics into cytosol 
a direct targeting strategy to cytosol, would be of prime importance. In order to achieve this 
objective, a novel approach using “cell penetrating peptides” (CPPs) or “protein 
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transduction domains” (PTDs) has been described. These peptides are tethered either 
directly to the therapeutic molecules or to the delivery system and then transported through 
cellular membrane. The cell penetrating peptides involve either chimeric CPPs like 
transportan and MPG or synthetic CPPs like oligoarginine and model amphipathic peptides 
(MAP). The protein transduction domains reported are penetratin and Tat peptide (Said 
Hassane et al., 2010). CPPs were successful in transporting many therapeutics and carriers 
such as proteins, DNA, antibodies and liposomes, nanoparticles into the mammalian cells 
(Gupta et al., 2005). 
7.E GOLGI APPARATUS  
Camillo Golgi more than 100 years ago first described the Golgi apparatus as ‘internal 
reticular apparatus’. Golgi apparatus is central organelle of the cell secretory pathway and 
interacts with ER on both sides of the stack. It is comprised of a flattened stacks of cisternae 
arranged into a ribbon that are punctuated by openings of various sizes through which 
tubules project and vesicles move. Golgi apparatus mainly contains enzymes involved in 
processes like phosphorylation, acylation, glycosylation, methylation and sulphation which 
are post translational modification processes of newly synthesized proteins. The trans golgi 
network (TGN) is where cargo is sorted before it is sent to various organelles inside the cell 
and for secretion outside the cell (Marsh et al., 2002). Transport of cargo through golgi is 
bidirectional, one is anterograde (that is forward transport of cargo) and other is retrograde 
(transport of molecules backward within the golgi, and from the golgi to ER) and is 
mediated by vesicles, tubules or the process of cisternal progression/maturation. Both the 
anterograde and retrograde transport processes are mediated by coatomer protein complex I 
(COPI) dependent mechanism of vesicular transport (Marsh et al., 2002). The retrograde 
trafficking pathway gained importance since it involves delivery of drugs and 
macromolecules from endosomes to Golgi apparatus and to ER thus bypassing the acidic 
and hydrolytic environment of the lysosome. 
The retrograde transport route was mainly reported to be exploited by toxins like shiga 
toxin and shiga like toxin to reach ER where they translocate into cytosol to exert their toxic 
effect.  Movement of this toxin to ER is considered to follow a COPI independent process 
involving Rab6 which normally operates in cycling of enzymes from golgi apparatus to ER. 
Shiga toxin has two subunits A and B. Targeting property of the Shiga toxin resides in the B 
subunit of the toxin and subunit A involves in cell death.  The B subunit binds to the cell 
surface glycosphingolipid, globotriaosylceramide or Gb3 and internalizes the toxin in a 
receptor mediated endocytosis process. Gb3 is also shown to be expressed in antigen 
presenting cells such as dendritic cells and some B cells. The unique retrograde trafficking 
pathway of shiga toxin combined with the expression of Gb3 provides us with a strategy to 
deliver antigens to the MHC class I pathway of APC using shiga toxin as vector. It was also 
shown that expression of Gb3 was enhanced in various cancers such as ovarian carcinoma, 
lymphoma, breast cancer cells, astrocytoma cells, malignant meningiomas, colon cancer and 
testicular cancer. Thus, shiga toxin can also be used to target the cancerous tissues for 
diagnostic as well as therapeutic purposes. Finally, since the B subunits of the shiga toxin 
can be produced as a polypeptide it can be used to target drugs, genes or proteins (antigens) 
for treatment and diagnosis of cancer and for delivery of antigens to MHC class I pathway 
(Tarrago-Trani et al., 2007). 
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7.F PEROXISOMES 
Peroxisomes initially described as “microbodies” are single membrane bound organelles 
found in cytoplasm that encompass large variety of functions in all eukaryotic cells (Platta et 
al., 2007). Peroxisomes are multifunctional organelles responsible for a wide variety of 
biochemical and metabolic processes. Peroxisomes house biosynthetic pathways for bile 
acids, docosahexanenoic acids and ether phospholipids. By virtue of ǂ- and ǃ-oxidation 
reactions peroxisomes, degrade variety of fatty acids including 3-methyl-branched fatty 
acids, eicosanoids, prostaglandins, thromboxanes and leukotrienes. Detoxification of certain 
xenobiotics such as glyoxylate and hydrogen peroxide were also performed by peroxisomes 
(Wanders et al., 2006).    
Peroxisomal enzymes are encoded by nuclear genes and then transported into lumen of 
peroxisomes from cytosol. The peroxisomal enzymes destined for matrix are first recognized 
by a peroxisomal targeting signal (PTS) type 1 or 2 (PTS1 or PTS2). A group of specific 
protein called peroxins play crucial role in proper formation and trafficking of matrix 
enzymes. Two peroxin receptors Pex5p and Pex7p recognize the enzyme’s PTS1 and PTS2 
respectively. These peroxin receptors bind to the cargo in cytosol and transport the complex 
to peroxisome membrane. The peculiar feature of protein import to peroxisomes which is 
different from mitochondria is its ability to accommodate fully folded, oligomeric, and co-
factor bound proteins by shuttling receptors peroxins. Peroxins Pex 13p and Pex 14p which 
are membrane associated peroxins initiate the receptor/cargo docking. The translocation is 
then advanced by formation of RING membrane protein network which forms a larger 
complex the importomer from peroxins Pex2p, Pex 10p, ad Pex12p (Rosenkranz et al., 2006). 
Peroxisome membrane proteins are transported to membrane by chaperone peroxin Pex19p 
and other membrane-associated peroxins Pex3p and Pex16p. Subsequent to release of cargo 
Pex5p, Pex7p and Pex20p are exported back to cytosol for further transportation (Platta et 
al., 2007). 
Peroxisomal related disorders include peroxisome biogenesis disorders, single enzyme 
deficiencies, or pathological situations associated with oxidative stress. The peroxisome 
assembly, protein import and consequent metabolic pathways are severely affected if there 
are any defects in genes encoding peroxins. Sometimes this might also result in complete 
loss of peroxisomal function. Thus, it would be of great clinical value if therapeutic proteins 
can be transported to peroxisomes of above discussed disease conditions. 
As mentioned earlier peroxisomes have unique ability of internalizing fully folded and 
oligomeric proteins. Thus, in many peroxisome related conditions when therapeutic 
proteins or enzymes are targeted directly to peroxisomes they will alleviate the disease 
conditions. The most important criteria for a protein to be targeted to peroxisomes is that it 
should possess PTSs. PTS1 and PTS2 are the two PTSs. PTS1 is the best characterized as a 
short carboxy terminal sequence specifically recognized by the peroxin Pex5p and PTS2 is a 
N-terminal sequence recognized and transported by peroxin Pex7p (Miyata et al., 2009). 
In order to target proteins which do not possess these targeting signal related sequences can 
be easily introduced through recombinant DNA molecular biology. For example an SKL 
sequence can be introduced to make protein accessible to PTS1 receptor Pex5p. One 
important consideration is that the attached sequence must be accessible and should not be 
buried inside the protein. To make it accessible spacers such as polyglycine can be 
introduced (Terlecky et al., 2007). 
One classic example of peroxisomal targeting is administration of catalase enzyme in 
peroxisomal hypocatalasemia. In this condition, hydrogen peroxide and related ROS initiate 
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a ‘peroxisomal deterioration spiral’ which affect the peroxisomal import apparatus and 
hence catalase with weak KANL PTS1 is specifically affected. To overcome this, catalase was 
engineered such that it contains a high affinity SKL PTS1 and hence, its import into 
peroxisomes is enhanced. The results have shown that when catalase-SKL along with a cell 
penetrating peptide Pep-1 delivered into human hypocatalasemic fibroblasts, it reduced 
cellular hydrogen peroxide levels by 80% (Wood et al., 2006). 
The following table summarizes various nuclear import machineries and their substrates 
present in cellular organelles. 
 
Cellular Organelle Import Apparatus 
Substrates 
(Examples) 
References 
Nucleus Importin ǂ and ǃ Nuclear localization 
signals (SV40, 
GAL4) 
(Chan et al., 
2001) 
Mitochondria  ATP/ADP Carrier ATP, ADP (Mukhopadhyay 
et al., 2007) 
 TIM, TOM Mitochondrial 
targeting peptide 
(Hoshino et al., 
2004) 
 Mitochondrial 
membrane 
Triphenyl 
phosphinium, 
Dequalinium 
(Jauslin et al., 
2003), (D'Souza 
et al., 2003) 
Endosomes/lysosomes Folate, transferrin 
cell surface 
receptors 
Folic acid, 
Transferrin 
(Breunig et al., 
2008) 
Golgi Apparatus Coatomer protein 
complex 1 (COP I) 
Shiga toxin (Tarrago-Trani et 
al., 2007) 
Peroxisomes Peroxins Peroxisomal 
targeting signal 
(Miyata et al., 
2009) 
Table 2. Table of import machineries of various cellular organelles and their respective 
susbtrates. 
8. Conclusions and future perspectives 
The strategy of targeting therapeutics like small molecule drugs, proteins, enzymes, siRNA, 
DNA etc to specific cell population like cancer was proved to be successful. But that itself 
does not ensure the therapeutic efficiency of the molecule, since the molecule has to reach its 
intracellular target where it acts. Thus, it is very important to understand the concept of 
intracellular organelle targeting and intricacies involved therein. In order to establish a 
pattern for strategies it is first very important to understand how these intracellular 
organelles communicate with each other and how do they overcome the barriers due to 
intracellular environment. Next, it is very important to understand how do some natural 
viruses and other pathogens decode the intracellular processes and evade the organelle of 
interest and make it defective. When we combine both the strategies, we can definitely 
provide excellent strategies to target therapeutics of organelle of interest. Improvements in 
the field of polymer chemistry and molecular biology allowed us to design novel carriers 
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and signaling agents for targeting organelles with superior level of sophistication. Like other 
fields of biomedical research, targeting to organelles has to evolve from a laboratory 
experiments to clinical success. 
9. References 
Adlam, V. J., Harrison, J. C., Porteous, C. M., James, A. M., Smith, R. A., Murphy, M. P., et al. 
(2005). Targeting an antioxidant to mitochondria decreases cardiac ischemia-
reperfusion injury. FASEB J, 19. 9. (Jul 2005), 1088-1095.1530-6860.  
Akita, H., Kogure, K., Moriguchi, R., Nakamura, Y., Higashi, T., Nakamura, T., et al. (2010). 
Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: 
programmed endosomal escape and dissociation. J Control Release, 143. 3. (May 10 
2010), 311-317.1873-4995. 
Allen, T. M. (2002). Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer, 2. 10. 
(Oct 2002), 750-763.1474-175.  
Aridor, M., & Balch, W. E. (1999). Integration of endoplasmic reticulum signaling in health 
and disease. Nat Med, 5. 7. (Jul 1999), 745-751.1078-8956  
Bale, S. S., Kwon, S. J., Shah, D. A., Banerjee, A., Dordick, J. S., & Kane, R. S. (2010). 
Nanoparticle-mediated cytoplasmic delivery of proteins to target cellular 
machinery. ACS Nano, 4. 3. (Mar 23 2010), 1493-1500.1936-086. 
Bareford, L. M., & Swaan, P. W. (2007). Endocytic mechanisms for targeted drug delivery. 
Adv Drug Deliv Rev, 59. 8. (Aug 10 2007), 748-758.0169-409. 
Behr, J. P. (1994). Gene transfer with synthetic cationic amphiphiles: prospects for gene 
therapy. Bioconjug Chem, 5. 5. (Sep-Oct 1994), 382-389.1043-1802. 
Bergen, J. M., von Recum, H. A., Goodman, T. T., Massey, A. P., & Pun, S. H. (2006). Gold 
nanoparticles as a versatile platform for optimizing physicochemical parameters for 
targeted drug delivery. Macromol Biosci, 6. 7. (Jul 14 2006), 506-516.1616-5187. 
Biasutto, L., Dong, L. F., Zoratti, M., & Neuzil, J. (2010). Mitochondrially targeted anti-cancer 
agents. Mitochondrion(Jul 1 2010).1872-8278. 
Bieber, T., Meissner, W., Kostin, S., Niemann, A., & Elsasser, H. P. (2002). Intracellular route 
and transcriptional competence of polyethylenimine-DNA complexes. J Control 
Release, 82. 2-3. (Aug 21 2002), 441-454.0168-3659. 
Bontha, S., Kabanov, A. V., & Bronich, T. K. (2006). Polymer micelles with cross-linked ionic 
cores for delivery of anticancer drugs. J Control Release, 114. 2. (Aug 28 2006), 163-
174.0168-3659. 
Boyce, M., Bryant, K. F., Jousse, C., Long, K., Harding, H. P., Scheuner, D., et al. (2005). A 
selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. 
Science, 307. 5711. (Feb 11 2005), 935-939.1095-9203. 
Breunig, M., Bauer, S., & Goepferich, A. (2008). Polymers and nanoparticles: intelligent tools 
for intracellular targeting? Eur J Pharm Biopharm, 68. 1. (Jan 2008), 112-128.0939-
6411. 
Callahan, J., & Kopecek, J. (2006). Semitelechelic HPMA copolymers functionalized with 
triphenylphosphonium as drug carriers for membrane transduction and 
mitochondrial localization. Biomacromolecules, 7. 8. (Aug 2006), 2347-2356.1525-7797. 
Cartiera, M. S., Johnson, K. M., Rajendran, V., Caplan, M. J., & Saltzman, W. M. (2009). The 
uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials, 
30. 14. (May 2009), 2790-2798.1878-5905. 
www.intechopen.com
Nanocarriers for Cytosolic Drug and Gene Delivery in Cancer Therapy   
 
267 
Cattaruzza, F., Cottrell, G. S., Vaksman, N., & Bunnett, N. W. (2009). Endothelin-converting 
enzyme 1 promotes re-sensitization of neurokinin 1 receptor-dependent neurogenic 
inflammation. Br J Pharmacol, 156. 5. (Mar 2009), 730-739.1476-5381. 
Champion, J. A., Katare, Y. K., & Mitragotri, S. (2007). Particle shape: a new design 
parameter for micro- and nanoscale drug delivery carriers. J Control Release, 121. 1-
2. (Aug 16 2007), 3-9.1873-4995. 
Champion, J. A., & Mitragotri, S. (2006). Role of target geometry in phagocytosis. Proc Natl 
Acad Sci U S A, 103. 13. (Mar 28 2006), 4930-4934.0027-8424. 
Chan, C. K., & Jans, D. A. (2001). Enhancement of MSH receptor- and GAL4-mediated gene 
transfer by switching the nuclear import pathway. Gene Ther, 8. 2. (Jan 2001), 166-
171.0969-7128. 
Chen, Y., & Arriaga, E. A. (2007). Individual electrophoretic mobilities of liposomes and 
acidic organelles displaying pH gradients across their membranes. Langmuir, 23. 10. 
(May 8 2007), 5584-5590.0743-7463. 
Chinnery, P. F., Taylor, R. W., Diekert, K., Lill, R., Turnbull, D. M., & Lightowlers, R. N. 
(1999). Peptide nucleic acid delivery to human mitochondria. Gene Ther, 6. 12. (Dec 
1999), 1919-1928.0969-7128. 
Conner, S. D., & Schmid, S. L. (2003). Regulated portals of entry into the cell. Nature, 422. 
6927. (Mar 6 2003), 37-44.0028-0836. 
Corona, P., Lamantea, E., Greco, M., Carrara, F., Agostino, A., Guidetti, D., et al. (2002). 
Novel heteroplasmic mtDNA mutation in a family with heterogeneous clinical 
presentations. Ann Neurol, 51. 1. (Jan 2002), 118-122.0364-5134. 
Cronshaw, J. M., & Matunis, M. J. (2004). The nuclear pore complex: disease associations and 
functional correlations. Trends Endocrinol Metab, 15. 1. (Jan-Feb 2004), 34-39.1043-
2760. 
D'Souza, G. G., Boddapati, S. V., & Weissig, V. (2005). Mitochondrial leader sequence--
plasmid DNA conjugates delivered into mammalian cells by DQAsomes co-localize 
with mitochondria. Mitochondrion, 5. 5. (Oct 2005), 352-358.1567-7249. 
D'Souza, G. G., Rammohan, R., Cheng, S. M., Torchilin, V. P., & Weissig, V. (2003). 
DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells. 
J Control Release, 92. 1-2. (Sep 19 2003), 189-197.0168-3659. 
D'Souza, G. G., & Weissig, V. (2009). Subcellular targeting: a new frontier for drug-loaded 
pharmaceutical nanocarriers and the concept of the magic bullet. Expert Opin Drug 
Deliv, 6. 11. (Nov 2009), 1135-1148.1744-7593. 
Dauty, E., & Verkman, A. S. (2004). Molecular crowding reduces to a similar extent the 
diffusion of small solutes and macromolecules: measurement by fluorescence 
correlation spectroscopy. J Mol Recognit, 17. 5. (Sep-Oct 2004), 441-447.0952-3499. 
Davis, J. R., Kakar, M., & Lim, C. S. (2007). Controlling protein compartmentalization to 
overcome disease. Pharm Res, 24. 1. (Jan 2007), 17-27.0724-8741. 
de Moura, M. B., dos Santos, L. S., & Van Houten, B. (2010). Mitochondrial dysfunction in 
neurodegenerative diseases and cancer. Environ Mol Mutagen, 51. 5. (Jun 2010), 391-
405.1098-2280. 
Dhaunsi, G. S. (2005). Molecular mechanisms of organelle biogenesis and related metabolic 
diseases. Med Princ Pract, 14 Suppl 1. 2005), 49-57.1011-7571. 
Dohner, K., Nagel, C. H., & Sodeik, B. (2005). Viral stop-and-go along microtubules: taking a 
ride with dynein and kinesins. Trends Microbiol, 13. 7. (Jul 2005), 320-327.0966-842. 
www.intechopen.com
 Biomedical Engineering, Trends, Research and Technologies 
 
268 
Draptchinskaia, N., Gustavsson, P., Andersson, B., Pettersson, M., Willig, T. N., Dianzani, I., 
et al. (1999). The gene encoding ribosomal protein S19 is mutated in Diamond-
Blackfan anaemia. Nat Genet, 21. 2. (Feb 1999), 169-175.1061-4036. 
Droogendijk, H. J., Kluin-Nelemans, H. J., van Doormaal, J. J., Oranje, A. P., van de 
Loosdrecht, A. A., & van Daele, P. L. (2006). Imatinib mesylate in the treatment of 
systemic mastocytosis: a phase II trial. Cancer, 107. 2. (Jul 15 2006), 345-351.0008-543. 
Dunne, M., Corrigan, I., & Ramtoola, Z. (2000). Influence of particle size and dissolution 
conditions on the degradation properties of polylactide-co-glycolide particles. 
Biomaterials, 21. 16. (Aug 2000), 1659-1668.0142-9612. 
Ellis, R. J., & Minton, A. P. (2003). Cell biology: join the crowd. Nature, 425. 6953. (Sep 4 
2003), 27-28.1476-4687. 
Fan, J., Hu, Z., Zeng, L., Lu, W., Tang, X., Zhang, J., et al. (2008). Golgi apparatus and 
neurodegenerative diseases. Int J Dev Neurosci, 26. 6. (Oct 2008), 523-534.0736-5748. 
Fattal, E., Couvreur, P., & Dubernet, C. (2004). "Smart" delivery of antisense oligonucleotides 
by anionic pH-sensitive liposomes. Adv Drug Deliv Rev, 56. 7. (Apr 23 2004), 931-
946.0169-409. 
Fominaya, J., & Wels, W. (1996). Target cell-specific DNA transfer mediated by a chimeric 
multidomain protein. Novel non-viral gene delivery system. J Biol Chem, 271. 18. 
(May 3 1996), 10560-10568.0021-9258. 
French, P. J., van Doorninck, J. H., Peters, R. H., Verbeek, E., Ameen, N. A., Marino, C. R., et 
al. (1996). A delta F508 mutation in mouse cystic fibrosis transmembrane 
conductance regulator results in a temperature-sensitive processing defect in vivo. J 
Clin Invest, 98. 6. (Sep 15 1996), 1304-1312.0021-9738. 
Fulda, S., Galluzzi, L., & Kroemer, G. (2010). Targeting mitochondria for cancer therapy. Nat 
Rev Drug Discov, 9. 6. (Jun 2010), 447-464.1474-1784. 
Galluzzi, L., Morselli, E., Kepp, O., Tajeddine, N., & Kroemer, G. (2008). Targeting p53 to 
mitochondria for cancer therapy. Cell Cycle, 7. 13. (Jul 1 2008), 1949-1955.1551-4005. 
Garner, M. M., & Burg, M. B. (1994). Macromolecular crowding and confinement in cells 
exposed to hypertonicity. Am J Physiol, 266. 4 Pt 1. (Apr 1994), C877-892.0002-9513. 
Gartner, J. (2000). Disorders related to peroxisomal membranes. J Inherit Metab Dis, 23. 3. 
(May 2000), 264-272.0141-8955. 
Geng, Y., Dalhaimer, P., Cai, S., Tsai, R., Tewari, M., Minko, T., et al. (2007). Shape effects of 
filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol, 2. 4. 
(Apr 2007), 249-255.1748-3395. 
Gillies, E. R., & Frechet, J. M. (2005). pH-Responsive copolymer assemblies for controlled 
release of doxorubicin. Bioconjug Chem, 16. 2. (Mar-Apr 2005), 361-368.1043-1802. 
Gonzalez-Angulo, A. M., Hennessy, B. T., & Mills, G. B. (2010). Future of personalized 
medicine in oncology: a systems biology approach. J Clin Oncol, 28. 16. (Jun 1 2010), 
2777-2783.1527-7755. 
Gratton, S. E., Ropp, P. A., Pohlhaus, P. D., Luft, J. C., Madden, V. J., Napier, M. E., et al. 
(2008). The effect of particle design on cellular internalization pathways. Proc Natl 
Acad Sci U S A, 105. 33. (Aug 19 2008), 11613-11618.1091-6490. 
Gupta, B., Levchenko, T. S., & Torchilin, V. P. (2005). Intracellular delivery of large 
molecules and small particles by cell-penetrating proteins and peptides. Adv Drug 
Deliv Rev, 57. 4. (Feb 28 2005), 637-651.0169-409. 
www.intechopen.com
Nanocarriers for Cytosolic Drug and Gene Delivery in Cancer Therapy   
 
269 
Hidvegi, T., Schmidt, B. Z., Hale, P., & Perlmutter, D. H. (2005). Accumulation of mutant 
alpha1-antitrypsin Z in the endoplasmic reticulum activates caspases-4 and -12, 
NFkappaB, and BAP31 but not the unfolded protein response. J Biol Chem, 280. 47. 
(Nov 25 2005), 39002-39015.0021-9258. 
Hill, C. S., & Treisman, R. (1995). Transcriptional regulation by extracellular signals: 
mechanisms and specificity. Cell, 80. 2. (Jan 27 1995), 199-211.0092-8674. 
Holt, I. J., Harding, A. E., & Morgan-Hughes, J. A. (1988). Deletions of muscle mitochondrial 
DNA in patients with mitochondrial myopathies. Nature, 331. 6158. (Feb 25 1988), 
717-719.0028-0836. 
Hope, M. J., Redelmeier, T. E., Wong, K. F., Rodrigueza, W., & Cullis, P. R. (1989). 
Phospholipid asymmetry in large unilamellar vesicles induced by transmembrane 
pH gradients. Biochemistry, 28. 10. (May 16 1989), 4181-4187.0006-2960. 
Hoshino, A., Fujioka, K., Oku, T., Nakamura, S., Suga, M., Yamaguchi, Y., et al. (2004). 
Quantum dots targeted to the assigned organelle in living cells. Microbiol Immunol, 
48. 12. 2004), 985-994.0385-5600. 
Hotamisligil, G. S. (2010). Endoplasmic reticulum stress and the inflammatory basis of 
metabolic disease. Cell, 140. 6. (Mar 19 2010), 900-917.1097-4172. 
Huang, X., Teng, X., Chen, D., Tang, F., & He, J. (2010). The effect of the shape of 
mesoporous silica nanoparticles on cellular uptake and cell function. Biomaterials, 
31. 3. (Jan 2010), 438-448.1878-5905. 
Hudis, C. A. (2007). Trastuzumab--mechanism of action and use in clinical practice. N Engl J 
Med, 357. 1. (Jul 5 2007), 39-51.1533-4406. 
Ito, D., & Suzuki, N. (2009). Seipinopathy: a novel endoplasmic reticulum stress-associated 
disease. Brain, 132. Pt 1. (Jan 2009), 8-15.1460-2156. 
Jauslin, M. L., Meier, T., Smith, R. A., & Murphy, M. P. (2003). Mitochondria-targeted 
antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress 
more effectively than untargeted antioxidants. FASEB J, 17. 13. (Oct 2003), 1972-
1974.1530-6860. 
Jensen, K. D., Nori, A., Tijerina, M., Kopeckova, P., & Kopecek, J. (2003). Cytoplasmic 
delivery and nuclear targeting of synthetic macromolecules. J Control Release, 87. 1-
3. (Feb 21 2003), 89-105.0168-3659. 
Johannsen, D. L., & Ravussin, E. (2009). The role of mitochondria in health and disease. Curr 
Opin Pharmacol, 9. 6. (Dec 2009), 780-786.1471-4973. 
Kao, H. P., Abney, J. R., & Verkman, A. S. (1993). Determinants of the translational mobility 
of a small solute in cell cytoplasm. J Cell Biol, 120. 1. (Jan 1993), 175-184.0021-9525. 
Koves, T. R., Ussher, J. R., Noland, R. C., Slentz, D., Mosedale, M., Ilkayeva, O., et al. (2008). 
Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal 
muscle insulin resistance. Cell Metab, 7. 1. (Jan 2008), 45-56.1550-4131. 
Lukacs, G. L., Haggie, P., Seksek, O., Lechardeur, D., Freedman, N., & Verkman, A. S. (2000). 
Size-dependent DNA mobility in cytoplasm and nucleus. J Biol Chem, 275. 3. (Jan 21 
2000), 1625-1629.0021-9258. 
Malouitre, S., Dube, H., Selwood, D., & Crompton, M. (2009). Mitochondrial targeting of 
cyclosporin A enables selective inhibition of cyclophilin-D and enhanced 
cytoprotection after glucose and oxygen deprivation. Biochem J, 425. 1. (Jan 1 2009), 
137-148.1470-8728. 
www.intechopen.com
 Biomedical Engineering, Trends, Research and Technologies 
 
270 
Marsh, B. J., & Howell, K. E. (2002). The mammalian Golgi--complex debates. Nat Rev Mol 
Cell Biol, 3. 10. (Oct 2002), 789-795.1471-0072. 
Maxfield, F. R., & McGraw, T. E. (2004). Endocytic recycling. Nat Rev Mol Cell Biol, 5. 2. (Feb 
2004), 121-132.1471-0072. 
Medalia, O., Typke, D., Hegerl, R., Angenitzki, M., Sperling, J., & Sperling, R. (2002). 
Cryoelectron microscopy and cryoelectron tomography of the nuclear pre-mRNA 
processing machine. J Struct Biol, 138. 1-2. (Apr-May 2002), 74-84.1047-8477. 
Mehta, A., Beck, M., Eyskens, F., Feliciani, C., Kantola, I., Ramaswami, U., et al. (2010). Fabry 
disease: a review of current management strategies. QJM, 103. 9. (Sep 2010), 641-
659.1460-2393. 
Mesika, A., Kiss, V., Brumfeld, V., Ghosh, G., & Reich, Z. (2005). Enhanced intracellular 
mobility and nuclear accumulation of DNA plasmids associated with a karyophilic 
protein. Hum Gene Ther, 16. 2. (Feb 2005), 200-208.1043-0342. 
Minton, A. P. (2006). How can biochemical reactions within cells differ from those in test 
tubes? J Cell Sci, 119. Pt 14. (Jul 15 2006), 2863-2869.0021-9533. 
Miyata, N., Hosoi, K., Mukai, S., & Fujiki, Y. (2009). In vitro import of peroxisome-targeting 
signal type 2 (PTS2) receptor Pex7p into peroxisomes. Biochim Biophys Acta, 1793. 5. 
(May 2009), 860-870.0006-3002. 
Mukhopadhyay, A., & Weiner, H. (2007). Delivery of drugs and macromolecules to 
mitochondria. Adv Drug Deliv Rev, 59. 8. (Aug 10 2007), 729-738.0169-409. 
Muratovska, A., Lightowlers, R. N., Taylor, R. W., Turnbull, D. M., Smith, R. A., Wilce, J. A., 
et al. (2001). Targeting peptide nucleic acid (PNA) oligomers to mitochondria 
within cells by conjugation to lipophilic cations: implications for mitochondrial 
DNA replication, expression and disease. Nucleic Acids Res, 29. 9. (May 1 2001), 
1852-1863.1362-4962. 
Narla, A., & Ebert, B. L. (2010). Ribosomopathies: human disorders of ribosome dysfunction. 
Blood, 115. 16. (Apr 22 2010), 3196-3205.1528-0020. 
Nori, A., Jensen, K. D., Tijerina, M., Kopeckova, P., & Kopecek, J. (2003). Tat-conjugated 
synthetic macromolecules facilitate cytoplasmic drug delivery to human ovarian 
carcinoma cells. Bioconjug Chem, 14. 1. (Jan-Feb 2003), 44-50.1043-1802. 
Nori, A., & Kopecek, J. (2005). Intracellular targeting of polymer-bound drugs for cancer 
chemotherapy. Adv Drug Deliv Rev, 57. 4. (Feb 28 2005), 609-636.0169-409. 
Nunnari, J., & Walter, P. (1996). Regulation of organelle biogenesis. Cell, 84. 3. (Feb 9 1996), 
389-394.0092-8674.  
Ozcan, U., Cao, Q., Yilmaz, E., Lee, A. H., Iwakoshi, N. N., Ozdelen, E., et al. (2004). 
Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. 
Science, 306. 5695. (Oct 15 2004), 457-461.1095-9203. 
Pante, N., & Kann, M. (2002). Nuclear pore complex is able to transport macromolecules 
with diameters of about 39 nm. Mol Biol Cell, 13. 2. (Feb 2002), 425-434.1059-1524. 
Panyam, J., Dali, M. M., Sahoo, S. K., Ma, W., Chakravarthi, S. S., Amidon, G. L., et al. (2003). 
Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-
co-glycolide) nano- and microparticles. J Control Release, 92. 1-2. (Sep 19 2003), 173-
187.0168-3659. 
Parkinson-Lawrence, E. J., Shandala, T., Prodoehl, M., Plew, R., Borlace, G. N., & Brooks, D. 
A. (2010). Lysosomal storage disease: revealing lysosomal function and physiology. 
Physiology (Bethesda), 25. 2. (Apr 2010), 102-115.1548-9221. 
www.intechopen.com
Nanocarriers for Cytosolic Drug and Gene Delivery in Cancer Therapy   
 
271 
Pastores, G. M., & Barnett, N. L. (2005). Current and emerging therapies for the lysosomal 
storage disorders. Expert Opin Emerg Drugs, 10. 4. (Nov 2005), 891-902.1744-7623. 
Petros, R. A., & DeSimone, J. M. (2010). Strategies in the design of nanoparticles for 
therapeutic applications. Nat Rev Drug Discov, 9. 8. (Aug 2010), 615-627.1474-1784. 
Platta, H. W., & Erdmann, R. (2007). The peroxisomal protein import machinery. FEBS Lett, 
581. 15. (Jun 19 2007), 2811-2819.0014-5793. 
Poon, I. K., & Jans, D. A. (2005). Regulation of nuclear transport: central role in development 
and transformation? Traffic, 6. 3. (Mar 2005), 173-186.1398-9219. 
Pouton, C. W., Wagstaff, K. M., Roth, D. M., Moseley, G. W., & Jans, D. A. (2007). Targeted 
delivery to the nucleus. Adv Drug Deliv Rev, 59. 8. (Aug 10 2007), 698-717.0169-409. 
Rajendran, L., Knolker, H. J., & Simons, K. (2010). Subcellular targeting strategies for drug 
design and delivery. Nat Rev Drug Discov, 9. 1. (Jan 2010), 29-42.1474-1784. 
Rosenkranz, K., Birschmann, I., Grunau, S., Girzalsky, W., Kunau, W. H., & Erdmann, R. 
(2006). Functional association of the AAA complex and the peroxisomal 
importomer. FEBS J, 273. 16. (Aug 2006), 3804-3815.1742-464. 
Rowe, S. M., Miller, S., & Sorscher, E. J. (2005). Cystic fibrosis. N Engl J Med, 352. 19. (May 12 
2005), 1992-2001.1533-4406. 
Said Hassane, F., Saleh, A. F., Abes, R., Gait, M. J., & Lebleu, B. (2010). Cell penetrating 
peptides: overview and applications to the delivery of oligonucleotides. Cell Mol 
Life Sci, 67. 5. (Mar 2010), 715-726.1420-9071. 
Samuelson, L. E., Dukes, M. J., Hunt, C. R., Casey, J. D., & Bornhop, D. J. (2009). TSPO 
targeted dendrimer imaging agent: synthesis, characterization, and cellular 
internalization. Bioconjug Chem, 20. 11. (Nov 2009), 2082-2089.1520-4812. 
Sanabria, H., Kubota, Y., & Waxham, M. N. (2007). Multiple diffusion mechanisms due to 
nanostructuring in crowded environments. Biophys J, 92. 1. (Jan 1 2007), 313-
322.0006-3495. 
Savic, R., Luo, L., Eisenberg, A., & Maysinger, D. (2003). Micellar nanocontainers distribute 
to defined cytoplasmic organelles. Science, 300. 5619. (Apr 25 2003), 615-618.1095-
9203. 
Schmid, S. L. (1997). Clathrin-coated vesicle formation and protein sorting: an integrated 
process. Annu Rev Biochem, 66. 1997), 511-548.0066-4154. 
Seksek, O., Biwersi, J., & Verkman, A. S. (1997). Translational diffusion of macromolecule-
sized solutes in cytoplasm and nucleus. J Cell Biol, 138. 1. (Jul 14 1997), 131-
142.0021-9525. 
Sheu, S. S., Nauduri, D., & Anders, M. W. (2006). Targeting antioxidants to mitochondria: a 
new therapeutic direction. Biochim Biophys Acta, 1762. 2. (Feb 2006), 256-265.0006-
3002. 
Tarrago-Trani, M. T., & Storrie, B. (2007). Alternate routes for drug delivery to the cell 
interior: pathways to the Golgi apparatus and endoplasmic reticulum. Adv Drug 
Deliv Rev, 59. 8. (Aug 10 2007), 782-797.0169-409. 
Terlecky, S. R., & Koepke, J. I. (2007). Drug delivery to peroxisomes: employing unique 
trafficking mechanisms to target protein therapeutics. Adv Drug Deliv Rev, 59. 8. 
(Aug 10 2007), 739-747.0169-409. 
Torchilin, V. P. (2005). Fluorescence microscopy to follow the targeting of liposomes and 
micelles to cells and their intracellular fate. Adv Drug Deliv Rev, 57. 1. (Jan 2 2005), 
95-109.0169-409. 
www.intechopen.com
 Biomedical Engineering, Trends, Research and Technologies 
 
272 
Ungar, D. (2009). Golgi linked protein glycosylation and associated diseases. Semin Cell Dev 
Biol, 20. 7. (Sep 2009), 762-769.1096-3634. 
Wanders, R. J., & Waterham, H. R. (2006). Biochemistry of mammalian peroxisomes 
revisited. Annu Rev Biochem, 75. 2006), 295-332.0066-4154. 
Warren, G., & Wickner, W. (1996). Organelle inheritance. Cell, 84. 3. (Feb 9 1996), 395-
400.0092-8674. 
Watson, P., Jones, A. T., & Stephens, D. J. (2005). Intracellular trafficking pathways and drug 
delivery: fluorescence imaging of living and fixed cells. Adv Drug Deliv Rev, 57. 1. 
(Jan 2 2005), 43-61.0169-409. 
Weissig, V., D'Souza, G. G., & Torchilin, V. P. (2001). DQAsome/DNA complexes release 
DNA upon contact with isolated mouse liver mitochondria. J Control Release, 75. 3. 
(Aug 10 2001), 401-408.0168-3659. 
Weissig, V., Lizano, C., & Torchilin, V. P. (2000). Selective DNA release from 
DQAsome/DNA complexes at mitochondria-like membranes. Drug Deliv, 7. 1. 
(Jan-Mar 2000), 1-5.1071-7544. 
Wood, C. S., Koepke, J. I., Teng, H., Boucher, K. K., Katz, S., Chang, P., et al. (2006). 
Hypocatalasemic fibroblasts accumulate hydrogen peroxide and display age-
associated pathologies. Traffic, 7. 1. (Jan 2006), 97-107.1398-9219. 
Xiong, R., Li, Z., Mi, L., Wang, P. N., Chen, J. Y., Wang, L., et al. (2010). Study on the 
intracellular fate of Tat peptide-conjugated quantum dots by spectroscopic 
investigation. J Fluoresc, 20. 2. (Mar 2010), 551-556.1573-4994. 
Xu, C., Xie, J., Kohler, N., Walsh, E. G., Chin, Y. E., & Sun, S. (2008). Monodisperse magnetite 
nanoparticles coupled with nuclear localization signal peptide for cell-nucleus 
targeting. Chem Asian J, 3. 3. (Mar 7 2008), 548-552.1861-471. 
Yan, F. F., Casey, J., & Shyng, S. L. (2006). Sulfonylureas correct trafficking defects of 
disease-causing ATP-sensitive potassium channels by binding to the channel 
complex. J Biol Chem, 281. 44. (Nov 3 2006), 33403-33413.0021-9258. 
Yang, S. R., Lee, H. J., & Kim, J. D. (2006). Histidine-conjugated poly(amino acid) derivatives 
for the novel endosomolytic delivery carrier of doxorubicin. J Control Release, 114. 1. 
(Aug 10 2006), 60-68.0168-3659. 
Yang, Z., Zhang, Y., Yang, Y., Sun, L., Han, D., Li, H., et al. (2010). Pharmacological and 
toxicological target organelles and safe use of single-walled carbon nanotubes as 
drug carriers in treating Alzheimer disease. Nanomedicine, 6. 3. (Jun 2010), 427-
441.1549-9642. 
Yessine, M. A., & Leroux, J. C. (2004). Membrane-destabilizing polyanions: interaction with 
lipid bilayers and endosomal escape of biomacromolecules. Adv Drug Deliv Rev, 56. 
7. (Apr 23 2004), 999-1021.0169-409. 
 
 
www.intechopen.com
Biomedical Engineering, Trends, Research and Technologies
Edited by Dr. Sylwia Olsztynska
ISBN 978-953-307-514-3
Hard cover, 644 pages
Publisher InTech
Published online 08, January, 2011
Published in print edition January, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book is addressed to scientists and professionals working in the wide area of biomedical engineering,
from biochemistry and pharmacy to medicine and clinical engineering. The panorama of problems presented
in this volume may be of special interest for young scientists, looking for innovative technologies and new
trends in biomedical engineering.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Srinath Palakurthi, Venkata K. Yellepeddi and Ajay Kumar (2011). Nanocarriers for Cytosolic Drug and Gene
Delivery in Cancer Therapy, Biomedical Engineering, Trends, Research and Technologies, Dr. Sylwia
Olsztynska (Ed.), ISBN: 978-953-307-514-3, InTech, Available from:
http://www.intechopen.com/books/biomedical-engineering-trends-research-and-technologies/nanocarriers-for-
cytosolic-drug-and-gene-delivery-in-cancer-therapy
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
